Excellent response to olaparib in metastatic HR-positive, HER2-negative breast cancer with BRIP1 mutation. Kwapisz D, Verret B, Garcia C, Andre F, et al. Ann Oncol 2023;34:315-318.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Kwapisz D, Verret B, Garcia C, Andre F, et al. Excellent response to olaparib in metastatic HR-positive, HER2-negative breast cancer with BRIP1 mutation. Ann Oncol 2023;34:315-318.
PMID: 36813328